QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
QQQ   310.34 (+1.43%)
AAPL   159.28 (+1.19%)
MSFT   273.78 (+0.57%)
META   202.16 (+2.20%)
GOOGL   104.92 (+3.66%)
AMZN   100.61 (+2.97%)
TSLA   197.58 (+7.82%)
NVDA   261.99 (+1.15%)
NIO   9.27 (+5.94%)
BABA   83.70 (+3.33%)
AMD   95.93 (-0.91%)
T   18.54 (+0.27%)
F   11.72 (+4.83%)
MU   58.63 (+1.72%)
CGC   1.97 (+5.91%)
GE   92.18 (+2.51%)
DIS   96.54 (+2.46%)
AMC   4.41 (+3.28%)
PFE   40.66 (-0.37%)
PYPL   76.72 (+4.79%)
NFLX   305.79 (+0.22%)
NASDAQ:PYXS

Pyxis Oncology - PYXS Stock Forecast, Price & News

$2.20
-0.16 (-6.78%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.13
▼
$2.36
50-Day Range
$1.45
▼
$2.76
52-Week Range
$1.10
▼
$5.31
Volume
55,410 shs
Average Volume
104,225 shs
Market Capitalization
$77.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Pyxis Oncology MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Pyxis Oncology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.46) to ($3.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

947th out of 983 stocks

Pharmaceutical Preparations Industry

463rd out of 478 stocks

See Top Rated MarketRank™ Stocks Here

PYXS stock logo

About Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

PYXS Stock News Headlines

March 18, 2023 | seekingalpha.com
Pyxis starts dosing in early stage study of cancer therapy PYX-201
March 16, 2023 | finance.yahoo.com
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
March 21, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
February 13, 2023 | finance.yahoo.com
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
December 1, 2022 | markets.businessinsider.com
Pyxis Oncology Announces FDA Clearance Of Two IND Applications In Solid Tumors; Stock Up
December 1, 2022 | finance.yahoo.com
Pyxis Oncology Announces FDA Clearance of Two IND Applications
November 28, 2022 | finance.yahoo.com
A Pyxis Oncology, Inc. (NASDAQ:PYXS) insider increased their holdings last year
November 8, 2022 | 247wallst.com
Tang Capital Partners Buys PYXS / Pyxis Oncology After Q3 Results Reported
March 21, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
November 1, 2022 | msn.com
Recap: Pyxis Oncology Q3 Earnings
November 1, 2022 | finance.yahoo.com
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
October 19, 2022 | seekingalpha.com
PYXS Pyxis Oncology, Inc.
October 14, 2022 | finance.yahoo.com
Is Pyxis Oncology (NASDAQ:PYXS) In A Good Position To Invest In Growth?
October 2, 2022 | finance.yahoo.com
Pyxis Oncology, Inc. (PYXS)
September 14, 2022 | bizjournals.com
Alloy Therapeutics' venture studio is raising its first fund — under a new president
September 1, 2022 | reuters.com
Pyxis Oncology Inc
August 18, 2022 | bizjournals.com
The Petri Dish: Moderna CFO retires, again; Pyxis culls cancer pipeline
August 15, 2022 | tmcnet.com
Pyxis Oncology Reports Financial Results for the Second
August 15, 2022 | finance.yahoo.com
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
July 12, 2022 | finance.yahoo.com
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2022 | finance.yahoo.com
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
June 28, 2022 | finance.yahoo.com
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
June 21, 2022 | finance.yahoo.com
Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year
May 19, 2022 | finance.yahoo.com
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
May 13, 2022 | investing.com
Pyxis Oncology Reports Q1 Net Loss of $31.4M, Cash Position of $231M
May 13, 2022 | finance.yahoo.com
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 7, 2022 | finance.yahoo.com
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
See More Headlines
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

PYXS Company Calendar

Today
3/21/2023
Next Earnings (Estimated)
4/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PYXS
CUSIP
N/A
CIK
1782223
Web
www.pyxisoncology.com
Phone
617-221-9059
Fax
N/A
Employees
56
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,970,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-45.31%
Return on Assets
-40.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.62
Quick Ratio
10.62

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.98 per share
Price / Book
0.28

Miscellaneous

Outstanding Shares
35,100,000
Free Float
34,325,000
Market Cap
$77.22 million
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Mr. John L. Flavin M.B.A. (Age 51)
    MBA, Ph.D., Co-Founder & Independent Chairman
    Comp: $72.96k
  • Dr. Lara S. Sullivan M.D.
    MBA, CEO, Pres & Director
  • Ms. Pamela Yanchik Connealy M.B.A. (Age 60)
    Chief Financial Officer
    Comp: $466.7k
  • Dr. Jay M. Feingold M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $406.59k
  • Mr. Jitendra Wadhane (Age 42)
    Chief Accounting Officer, Sr. VP of Fin. & Corp. Controller
  • Dr. Balu N. Balasubramanian Ph.D.
    Interim Chief Technology Officer
  • Dr. Jan Pinkas Ph.D.
    Chief Scientific Officer
  • Ms. Martina Molsbergen B.S. (Age 57)
    Interim Chief Bus. Officer
  • Dr. Charles T. Gombar Ph.D.
    Sr. VP of Portfolio & Program Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PYXS Stock - Frequently Asked Questions

Should I buy or sell Pyxis Oncology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYXS shares.
View PYXS analyst ratings or view top-rated stocks.

How have PYXS shares performed in 2023?

Pyxis Oncology's stock was trading at $1.34 at the start of the year. Since then, PYXS stock has increased by 64.2% and is now trading at $2.20.
View the best growth stocks for 2023 here.

Are investors shorting Pyxis Oncology?

Pyxis Oncology saw a increase in short interest in February. As of February 28th, there was short interest totaling 167,700 shares, an increase of 49.6% from the February 13th total of 112,100 shares. Based on an average daily volume of 120,200 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the company's shares are sold short.
View Pyxis Oncology's Short Interest.

When is Pyxis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our PYXS earnings forecast.

When did Pyxis Oncology IPO?

(PYXS) raised $158 million in an IPO on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share.

What is Pyxis Oncology's stock symbol?

Pyxis Oncology trades on the NASDAQ under the ticker symbol "PYXS."

Who are Pyxis Oncology's major shareholders?

Pyxis Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (9.89%), Citigroup Inc. (1.02%), Geode Capital Management LLC (0.58%), Morgan Stanley (0.30%), Renaissance Technologies LLC (0.24%) and Bank of America Corp DE (0.18%). Insiders that own company stock include Darren S Cline, Mark Chin and Thomas Civik.
View institutional ownership trends.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pyxis Oncology's stock price today?

One share of PYXS stock can currently be purchased for approximately $2.20.

How much money does Pyxis Oncology make?

Pyxis Oncology (NASDAQ:PYXS) has a market capitalization of $77.22 million.

How can I contact Pyxis Oncology?

The official website for the company is www.pyxisoncology.com. The company can be reached via phone at 617-221-9059 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:PYXS) was last updated on 3/21/2023 by MarketBeat.com Staff